February 24, 2018

Do you have atrial fibrillation? Your input can help shape research to benefit afib patients.

Patients with atrial fibrillation are at higher risk of suffering stroke and other complications related to the development of blood clots in their heart. Until 2010, the only oral anticoagulant (blood thinner) to prevent strokes in Afib was warfarin (Coumadin®). Now there are two new oral anticoagulants available in the United States–dabigatran (Pradaxa®) and rivaroxaban […]

Atrial Fibrillation & Anticoagulants–StopAfib.org interviews Dr. Elaine Hylek

StopAfib.org interviews Dr. Elaine Hylek of Boston University. A transcript of this video, as well as additional information about the topics discussed, and Dr. Hylek, can be found at: http://www.stopafib.org/newsitem.cfm/NEWSID/349 In this video interview, Dr. Elaine Hylek of Boston University discusses new anticoagulant drugs for stroke prevention in atrial fibrillation. For many years, warfarin (Coumadin) […]

FDA Approves Alternative to Warfarin — Rivaroxaban (Xarelto) Approved for Atrial Fibrillation Stroke Prevention

The US Food and Drug Administration has approved Xarelto (rivaroxaban) to reduce stroke risk in those with non-valvular atrial fibrillation (afib unrelated to heart valve problems). Xarelto is now the second oral alternative to warfarin (Coumadin) and offers an option for those unable to take warfarin or dabigatran. Xarelto is the first once-a-day alternative to […]

Breaking News: FDA Panel Recommends Approval of Rivaroxaban (Xarelto) for Atrial Fibrillation Stroke Prevention

The US Food & Drug Administration (FDA) Advisory Committee just voted 9-2, with 1 abstaining, to recommend that the FDA approve rivaroxaban (Xarelto) for prevention of atrial fibrillation strokes. See our full story, now up at: FDA Panel Votes for Rivaroxaban: Atrial Fibrillation Patients May Soon Have Two Alternatives to Warfarin for Stroke Prevention

Rivaroxaban (Xarelto) Effective for Atrial Fibrillation Patients with High Stroke Risk

Just ahead of the FDA Advisory Committee hearing on rivaroxaban for stroke prevention in atrial fibrillation, we report in more depth on the ROCKET-AF trial results published recently in the New England Journal of Medicine. Rivaroxaban was shown to be as effective as warfarin (Coumadin) for stroke prevention in a high-risk afib population. To learn […]

Dr. Elaine Hylek on Xarelto and Pradaxa, New Alternatives to Warfarin (Coumadin) — Video

The US FDA has just announced that on September 8, 2011, the FDA Cardiovascular and Renal Drugs Advisory Committee will meet to review whether to recommend approval of rivaroxaban (brand name Xarelto), an alternative to warfarin, for stroke prevention in atrial fibrillation. In this recent video interview, Dr. Elaine Hylek, a leading anticoagulant authority, discussed […]

Breaking News: Rivaroxaban As Good as Warfarin for Atrial Fibrillation Stroke Prevention

In late breaking clinical trials presented today at the American Heart Association Scientific Sessions, results of the ROCKET AF trial indicated that in an atrial fibrillation patient population that was at a very high risk of stroke, rivaroxaban (Xarelto) was as good as warfarin at preventing strokes. Learn more at:  Rivaroxaban comparable to warfarin in […]